Tirzepatide Research: SURPASS, SURMOUNT, and the Extended Programme
The short version
Tirzepatide research spans roughly eight years from the first preclinical reports to a cardiovascular outcomes trial and studies in multiple organ systems. The core of the record is large and well-powered. The SURPASS programme in type 2 diabetes ran five randomised controlled trials plus a cardiovascular outcomes study. The SURMOUNT programme in obesity ran multiple trials including a 72-week head-to-head comparison against another approved agent in this class.
This page walks through the key trials and what they measured. Each finding is tagged by the type of evidence it represents — a randomised controlled trial carries different weight than a post-hoc analysis or a pharmacovigilance report. The gaps — things the trials have not yet confirmed — are noted where they exist.
Tirzepatide mechanism of action: the pharmacological foundation
The 2018 discovery paper (Coskun et al., Mol Metab) reported that LY3298176 — the molecule that became tirzepatide — activated both the GIP receptor and the GLP-1 receptor in cell-based signalling assays. In mice, chronic administration reduced body weight and food intake more than a selective GLP-1 receptor agonist. Phase 1 work in 142 subjects demonstrated once-weekly PK and reductions in fasting glucose and body weight versus placebo [1].
A 2020 in vitro characterisation (Willard et al., JCI Insight) identified tirzepatide as an imbalanced dual agonist — engaging the GIP receptor more fully than the GLP-1 receptor — and documented biased GLP-1 receptor signalling that preferentially activates the cAMP pathway over beta-arrestin recruitment. Beta-arrestin1 limits the insulin secretion response to native GLP-1; tirzepatide's biased profile avoids this brake, which is proposed to enhance net insulin output [2].
The broader dual-incretin class perspective appears in Campbell et al. (Cell Metab, 2023), situating tirzepatide within decades of research on combined GIP and GLP-1 biology and the evolution of unimolecular dual agonists [20].
SURPASS programme: type 2 diabetes results
SURPASS-2 enrolled 1,879 adults with type 2 diabetes in an open-label 40-week randomised trial. The primary endpoint was change in HbA1c (glycated haemoglobin — a blood marker reflecting average glucose over roughly three months). Tirzepatide 5, 10, and 15 mg reduced HbA1c by 2.01, 2.24, and 2.30 percentage points respectively, versus 1.86 percentage points with the active comparator. All three tirzepatide doses were non-inferior and statistically superior. Reductions in body weight were also greater with tirzepatide: treatment differences of −1.9, −3.6, and −5.5 kg [3]. Gastrointestinal adverse events were the most common and were mostly mild to moderate [3].
SURPASS J-mono, a prespecified analysis in 636 Japanese adults with type 2 diabetes over 52 weeks, found that all three tirzepatide doses significantly improved measures of insulin sensitivity (HOMA2-%S) and beta-cell function (HOMA2-%B) versus the comparator, and significantly reduced fasting insulin and C-peptide [35].
The SURPASS-CVOT cardiovascular outcomes trial registered at ClinicalTrials.gov (NCT04255433) compared tirzepatide with dulaglutide in adults with type 2 diabetes and established cardiovascular disease [32].
Tirzepatide weight loss: SURMOUNT programme results
SURMOUNT-1 is the foundational obesity efficacy trial: a 72-week double-blind randomised controlled trial in 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related comorbidity) and without type 2 diabetes. Tirzepatide produced mean body weight changes of −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. Gastrointestinal adverse events were the most common, primarily during dose escalation and mostly mild to moderate [4].
A post-hoc analysis of 1,605 SURMOUNT-1 participants examined cardiometabolic risk factor changes by degree of weight loss. Participants reaching ≥35% body weight reduction showed mean changes up to: systolic blood pressure −14.2 mmHg (95% CI −16.1 to −12.3), diastolic −9.2 mmHg, waist circumference −32.4 cm, and HOMA-IR −59.7%. HbA1c and HOMA-IR decreased even with modest weight loss; lipid improvements were observed primarily after >10% weight reduction [19].
SURMOUNT-4 examined continuation versus withdrawal. Participants switched to placebo after an initial loss phase regained weight; those continuing tirzepatide maintained and extended their losses [28]. A post-hoc analysis of SURMOUNT-4 found weight regain after stopping was accompanied by worsening of systolic blood pressure, waist circumference, and cardiometabolic markers [29].
Tirzepatide vs semaglutide: the head-to-head data
SURMOUNT-5 placed the two drugs directly against each other in 751 adults with obesity without type 2 diabetes, randomised to maximum tolerated doses (tirzepatide 10 or 15 mg; comparator 1.7 or 2.4 mg) once weekly for 72 weeks. The least-squares mean weight change was −20.2% with tirzepatide versus −13.7% with the comparator (P < 0.001). Tirzepatide also produced greater reductions in waist circumference and higher proportions reaching each 5-percentage-point threshold of weight loss [5].
SURPASS-2 had shown earlier that tirzepatide was superior to the comparator for HbA1c reduction in type 2 diabetes (differences at 5/10/15 mg: 0.15/0.39/0.44 pp) and greater weight reduction (differences −1.9/−3.6/−5.5 kg) [3].
The SURMOUNT-5 data represent the first prospective head-to-head trial in obesity; earlier comparisons were cross-trial or modelled.
Tirzepatide results in extended indications
The trial programme has extended beyond type 2 diabetes and obesity to several associated conditions.
Obstructive sleep apnea: SURMOUNT-OSA randomised adults with obesity and moderate-to-severe obstructive sleep apnea to tirzepatide or placebo for 52 weeks. The primary endpoint was change in the apnea-hypopnea index (AHI — the count of breathing disruptions per hour of sleep). Tirzepatide produced significant reductions in AHI alongside weight loss [16]. This trial supported the third FDA approval.
Heart failure with preserved ejection fraction (HFpEF): The SUMMIT trial in adults with HFpEF and obesity reported improvements in the primary functional endpoint — the six-minute walk distance test — and in Kansas City Cardiomyopathy Questionnaire scores at 52 weeks, alongside significant weight reduction [17].
Metabolic dysfunction-associated steatohepatitis (MASH): The SYNERGY-NASH trial evaluated tirzepatide in adults with MASH (formerly called NASH — a form of fatty liver disease characterised by inflammation and fibrosis) and found significant improvements in liver histology [30].
A network meta-analysis of 31 randomised controlled trials (more than 35,000 participants) placed tirzepatide 15 mg in the top three for weight-related parameters, glycaemic profile, lipid parameters, and blood pressure. The estimated risk ratio for achieving ≥15% weight loss versus placebo was 10.24 (95% CI 6.42–16.34) [18].
The cardiovascular outcomes trial SURPASS-CVOT, registered at ClinicalTrials.gov (NCT04255433), is evaluating major adverse cardiovascular events with tirzepatide versus dulaglutide in type 2 diabetes with established cardiovascular disease [32].
For Tirzepatide references to every cited study, see the references page.